Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Current Leases (2021 - 2025)

Lyra Therapeutics has reported Current Leases over the past 5 years, most recently at $4.8 million for Q4 2025.

  • Quarterly results put Current Leases at $4.8 million for Q4 2025, up 16.91% from a year ago — trailing twelve months through Dec 2025 was $4.8 million (up 16.91% YoY), and the annual figure for FY2025 was $4.8 million, up 16.91%.
  • Current Leases for Q4 2025 was $4.8 million at Lyra Therapeutics, up from $4.7 million in the prior quarter.
  • Over the last five years, Current Leases for LYRA hit a ceiling of $5.4 million in Q4 2023 and a floor of $654000.0 in Q3 2022.
  • Median Current Leases over the past 5 years was $1.8 million (2023), compared with a mean of $2.7 million.
  • Biggest five-year swings in Current Leases: plummeted 37.83% in 2022 and later surged 250.81% in 2023.
  • Lyra Therapeutics' Current Leases stood at $1.1 million in 2021, then surged by 44.23% to $1.5 million in 2022, then surged by 250.81% to $5.4 million in 2023, then fell by 24.16% to $4.1 million in 2024, then grew by 16.91% to $4.8 million in 2025.
  • The last three reported values for Current Leases were $4.8 million (Q4 2025), $4.7 million (Q3 2025), and $4.6 million (Q2 2025) per Business Quant data.